Blinatumomab + ponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults.

Abstract:

:We retrospectively examined the results of a new chemo-free approach combining blinatumomab with ponatinib (blina/pona) in 26 relapsed/refractory Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) patients. All but one achieved complete morphologic remission, and 23 achieved a complete molecular response. With a median follow-up of 34.4 months, the median overall (OS) and event-free (EFS) survivals were 20 and 15.3 months, respectively. After blina/pona, 8 patients underwent an allotransplant (allo), while among the 18 non-transplanted cases, 15 received ponatinib in maintenance. Fifteen relapse/progressions occurred with a significant difference between allo and non allo cases (12.5% vs 82.3%, p = 0.003). However, OS and EFS were similar between both groups. Finally, blina/pona was well tolerated with eight reversible neurologic events and three cytokine release syndromes. Prospective studies are needed to properly assess the safety, tolerability and efficacy of the combination therapy.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Couturier MA,Thomas X,Raffoux E,Huguet F,Berthon C,Simand C,Gallego-Hernanz MP,Hicheri Y,Hunault Berger M,Saillard C,Leguay T,Loiseau C,Béné MC,Chevallier P

doi

10.1080/10428194.2020.1844198

subject

Has Abstract

pub_date

2020-11-06 00:00:00

pages

1-10

eissn

1042-8194

issn

1029-2403

pub_type

杂志文章
  • Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea.

    abstract::Hydroxyurea (HU) has traditionally been the first-line treatment for patients with polycythemia vera (PV) or essential thrombocythemia (ET) at high risk for vascular complications. However, approximately 20-25% of patients develop resistance or intolerance to HU and must be treated with second-line therapies. Resistan...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2014.893310

    authors: Sever M,Newberry KJ,Verstovsek S

    更新日期:2014-12-01 00:00:00

  • Is there a difference in childhood T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma?

    abstract::To distinguish the similarities or differences between T-cell acute lymphoblastic leukaemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL), we retrospectively analyzed the clinical, immunophenotypic, cytogenetic, and molecular characteristics in 37 children diagnosed between December 1990 and December 2003. Compara...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190701509772

    authors: Uyttebroeck A,Vanhentenrijk V,Hagemeijer A,Boeckx N,Renard M,Wlodarska I,Vandenberghe P,Depaepe P,De Wolf-Peeters C

    更新日期:2007-09-01 00:00:00

  • Primary breast lymphoma.

    abstract::Primary breast lymphoma (PBL) is a rare form of localized extranodal lymphoma. Few reports are available in the literature concerning its treatment and outcome. Of the 34 cases of PBL seen at our institution over a 25-year period, 20 consecutive cases were treated with CHOP or CHOP-like chemotherapy regimen and had ad...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/1042819031000079195

    authors: Gholam D,Bibeau F,El Weshi A,Bosq J,Ribrag V

    更新日期:2003-07-01 00:00:00

  • Transient abnormal myelopoiesis in Down's syndrome.

    abstract::Recent data have elucidated the pathogenesis of transient abnormal myelopoiesis (TAM) to a great extent. TAM is a monoclonal disorder which resolves spontaneously and the target cell in this disorder is a multipotent stem cell which is capable of differentiating into megakaryocytes. The pathogeneses of TAM/AMKL (acute...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199209051029

    authors: Kurahashi H,Hara J,Yumura-Yagi K,Tawa A,Kawa-Ha K

    更新日期:1992-12-01 00:00:00

  • Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone.

    abstract::The addition of rituximab (R) to standard CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy has altered the significance of previously recognized prognostic factors. We sought to re-examine the prognostic utility of (1) the number of extranodal sites of disease involvement, and (2) a prima...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2010.504872

    authors: Hui D,Proctor B,Donaldson J,Shenkier T,Hoskins P,Klasa R,Savage K,Chhanabhai M,Gascoyne RD,Connors JM,Sehn LH

    更新日期:2010-09-01 00:00:00

  • Predicting long-term survival in multiple myeloma patients following autotransplants.

    abstract::Multiple myeloma is a B-cell malignancy with a highly variable outcome. Despite the marked recent improvements in its management, especially due to the widespread application of high-dose treatment and autologous stem cell transplantation, relapses eventually occur in the majority of patients. Systematic research at U...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/1042819031000067567

    authors: Fassas AB,Van Rhee F,Tricot G

    更新日期:2003-05-01 00:00:00

  • DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphoma.

    abstract::We performed a phase II study of dexamethasone, ifosfamide, idarubicin and etoposide (DIZE) in patients with relapsed or refractory Hodgkin's (HL) and non-Hodgkin's lymphoma (NHL). The regimen consisted of dexamethasone (20 mg i.v. days 1-4), idarubicin (8 mg/m2 i.v. days 1+2), continuous infusion (c.i.) of ifosfamide...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.3109/10428199809059229

    authors: Reiser M,Schnell R,Straub G,Borchmann P,Wilhelm M,Ubelacker R,Wörmann B,Münch R,Diehl V,Engert A

    更新日期:1998-10-01 00:00:00

  • Cytotoxicity of cytokine-induced killer cells coated with bispecific antibody against acute myeloid leukemia cells.

    abstract::Various types of cytokines have been used in in vitro experiments to generate cytokine-induced killer (CIK) cells that are reactive to patient acute myeloid leukemia (AML) cells. Of these CIK cells, interleukin-2 (IL-2)-activated peripheral blood mononuclear cells, i.e., lymphokine-activated killer (LAK) cells, with t...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199409049672

    authors: Kaneko T,Fusauch Y,Kakui Y,Okumura K,Mizoguchi H,Oshimi K

    更新日期:1994-07-01 00:00:00

  • Plasma cell tumors in HIV-positive patients: report of a case and review of the literature.

    abstract::Plasma cell tumors show an increased incidence in HIV-positive patients. The cases reported in the literature suggest that plasma cell tumors occur in a younger age group than that encountered in the general population. Pathologically, many of these tumors show a plasmablastic morphology. Plasma cell tumors in HIV-pos...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190500054566

    authors: Salarieh A,Rao C,Gottesman SR,Alagha O,Todor R,Axiotis CA

    更新日期:2005-07-01 00:00:00

  • Prevention of menstruation with leuprorelin (GnRH agonist) in women undergoing myelosuppressive chemotherapy or radiochemotherapy for hematological malignancies: a pilot study.

    abstract::Vaginal bleeding during aplasia can induce transfusion support, infection and discomfort. Oral and intramuscular hormonotherapy can be toxic and/or difficult to manage (mucositis). This single-center pilot study evaluated the efficacy and safety of leuprorelin (L) in preventing heavy vaginal bleeding in 20 nonmenopaus...

    journal_title:Leukemia & lymphoma

    pub_type: 临床试验,杂志文章

    doi:10.3109/10428190109097723

    authors: Lhommé C,Brault P,Bourhis JH,Pautier P,Dohollou N,Dietrich PY,Akbar-Zadeh G,Lucas C,Pico JL,Hayat M

    更新日期:2001-09-01 00:00:00

  • In vivo pharmacodynamic effects of Hu1D10 (remitogen), a humanized antibody reactive against a polymorphic determinant of HLA-DR expressed on B cells.

    abstract::The humanized monoclonal antibody Hu1D10 (Remitogen, Protein Design Labs, Fremont, CA) recognizes a polymorphic determinant of human leukocyte antigen-DR expressed on the majority of B-cell lymphomas and on normal B cells of most individuals. Hu1D10 mediates complement-mediated cytotoxicity, antibody-dependent cell-me...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190290026376

    authors: Shi JD,Bullock C,Hall WC,Wescott V,Wang H,Levitt DJ,Klingbeil CK

    更新日期:2002-06-01 00:00:00

  • Improved survival using an intensive, pediatric-based chemotherapy regimen in adults with T-cell acute lymphoblastic leukemia.

    abstract::All patients with newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) and treated over a 17-year period at a single institution were retrospectively analyzed. From 1990 to 2000, 40 patients were treated with a variety of adult-based ALL regimens. From 2000 to 2007, a pediatric-based protocol, DFCI (Dana Farber...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190903388376

    authors: Al-Khabori M,Minden MD,Yee KW,Gupta V,Schimmer AD,Schuh AC,Xu W,Brandwein JM

    更新日期:2010-01-01 00:00:00

  • Invasive mold infections: recent advances in management approaches.

    abstract::An increasing number of patients are undergoing transplantation procedures or receiving aggressive immunosuppression and chemotherapy. The growing population of immunocompromised hosts has led to a rise in the prevalence of invasive fungal infections (IFIs) due to yeasts and molds. Recent trends suggest that patients ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190902777434

    authors: Chandrasekar P

    更新日期:2009-05-01 00:00:00

  • Poor outcome of adult acute lymphoblastic leukemia patients carrying the (1;19)(q23;p13) translocation.

    abstract::The (1;19)(q23;p13) translocation, leading to the production of the E2A/PBX1 fusion transcript, is one of the most common translocations in pediatric B-lineage acute lymphoblastic leukemia (ALL). It was assumed to be associated with a poor clinical outcome, although intensive therapy and bone marrow transplantation ha...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190500331261

    authors: Piccaluga PP,Malagola M,Rondoni M,Ottaviani E,Testoni N,Laterza C,Visani G,Pileri SA,Martinelli G,Baccarani M

    更新日期:2006-03-01 00:00:00

  • Gravin gene expression in acute leukaemias: clinical importance and review of the literature.

    abstract::The aim of this study was to determine the expression of Gravin (a tumor suppressor gene belonging to the A kinase anchoring protein family) in samples of acute leukaemia and to explore its association with the prognosis. The study group consisted of 162 people (137 patients with acute leukaemia and 25 volunteers as c...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190701377055

    authors: Yildirim M,Paydas S,Tanriverdi K,Seydaoglu G,Disel U,Yavuz S

    更新日期:2007-06-01 00:00:00

  • Treatment of refractory T-cell chronic lymphocytic leukemia with purine nucleoside analogues.

    abstract::This report describes two cases of T-cell chronic lymphocytic leukemia (T-CLL) treated with purine nucleoside analogues. One patient had CD8+, CD3+ large granular lymphocytosis (LGL) producing transfusion-dependent anemia and was refractory to chemotherapy. Treatment with four cycles of fludarabine produced a clinical...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199409049659

    authors: Witzig TE,Weitz JJ,Lundberg JH,Tefferi A

    更新日期:1994-06-01 00:00:00

  • Emerging molecular predictive and prognostic factors in acute myeloid leukemia.

    abstract::Recurrent cytogenetic abnormalities have provided the backbone for prognosticating acute myeloid leukemia and predicting response to consolidative therapies for decades. However, more than 45% of acute myeloid leukemia patients have normal cytogenetics on both karyotype and fluorescence in situ hybridization at diagno...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2017.1393669

    authors: McCurdy SR,Levis MJ

    更新日期:2018-09-01 00:00:00

  • Blastic natural killer (NK)-cell lymphoma: report of an unusual CD4 negative case and review of the CD4 negative neoplasms with blastic features in the literature.

    abstract::Blastic Natural Killer (NK)-cell lymphoma is a relatively new entity which has been recently included in the WHO classification. CD4 expression is observed in most cases of blastic NK-cell lymphomas and has been related with skin tropism. We report an unusual CD4 negative blastic NK-cell lymphoma with primary presenta...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190410001723232

    authors: Argyrakos T,Rontogianni D,Karmiris T,Kapsimali V,Grigoriou E,Tsantekidou M,Naum C,Galani V,Pantelidaki C,Harhalakis N,Nikiforakis E,Kanavaros P

    更新日期:2004-10-01 00:00:00

  • Angiogenic and lymphangiogenic molecules in hematological malignancies.

    abstract::In this review, the role of angiogenic and lymphangiogenic growth factors in hematological malignancies is summarized, alongside with possible therapeutic applications. Recent data demonstrate the importance of angiogenesis in hematologic malignancies including leukemia, lymphoma, and multiple myeloma. Expression of a...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190290005964

    authors: Orpana A,Salven P

    更新日期:2002-02-01 00:00:00

  • Chromosomal imbalances in pediatric Burkitt-like lymphoma and review of the literature in relation to other germinal center derived B-cell tumors.

    abstract::This study reports on the cytogenetic features of a novel case of pediatric Burkitt-like lymphoma (BLL), that adds to the three published. Four groups of cytogenetic abnormalities were detected in the present case: (1) imbalances shared by most germinal center (GC) derived B-cell tumors including BLL (+1q, -6q, -8p, +...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190600880118

    authors: Pezzolo A,Cinti R,Negri F,Parodi F,Garaventa A,Gambini C,Pistoia V

    更新日期:2006-11-01 00:00:00

  • Alterations of P53 and RB genes and the evolution of the accelerated phase of chronic myeloid leukemia.

    abstract::Using the single-strand conformation polymorphism and heteroduplex analyses, the P53 and RB genes were analyzed in cell samples from twenty-eight patients with chronic myeloid leukemia (CML) both at diagnosis and at the onset of accelerated phase (AP) of the disease. No alterations of the P53 or RB genes were found in...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190009059278

    authors: Beck Z,Kiss A,Tóth FD,Szabó J,Bácsi A,Balogh E,Borbély A,Telek B,Kovács E,Oláh E,Rak K

    更新日期:2000-08-01 00:00:00

  • The function of cyclic-adenosine monophosphate responsive element-binding protein in hematologic malignancies.

    abstract::Central to discovering novel approaches to treating leukemias and lymphomas is a clear understanding of the signaling networks which lead to unchecked cell cycle progression, proliferation, and survival. Cyclic-adenosine monophosphate (cAMP) responsive element-binding protein (CREB) represents a critical integrator of...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428194.2011.584994

    authors: Mitton B,Cho EC,Aldana-Masangkay GI,Sakamoto KM

    更新日期:2011-11-01 00:00:00

  • A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254.

    abstract::Anti-B4-blocked ricin (anti-B4-bR) is a potent immunotoxin directed against the CD19 antigen. Previous phase I and II studies suggested a possible role for anti-B4-bR as consolidation after high-dose chemotherapy and autologous stem cell transplant. Cancer and Leukemia Group B (CALGB) 9254 is a phase III study which r...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.3109/10428194.2010.543714

    authors: Furman RR,Grossbard ML,Johnson JL,Pecora AL,Cassileth PA,Jung SH,Peterson BA,Nadler LM,Freedman A,Bayer RL,Bartlett NL,Hurd DD,Cheson BD,Cancer Leukemia Group B.,Eastern Cooperative Oncology Group.

    更新日期:2011-04-01 00:00:00

  • The role of aberrant transcription factor in the progression of chronic myeloid leukemia.

    abstract::Chronic myeloid leukemia (CML) is a hematopoietic stem cell disease with distinct biological and clinical features. The Philadelphia (Ph) chromosome and BCR/ABL fusion gene is the major cytogenetic and molecular marker of CML chronic phase. However, the molecular mechanisms of disease progression are not well known. R...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190802163305

    authors: Zhang S

    更新日期:2008-08-01 00:00:00

  • In vivo accumulation of etoposide in peripheral leukemic cells in patients treated for acute myeloblastic leukemia; relation to plasma concentrations and protein binding.

    abstract::Since etoposide interacts with the nuclear enzyme topoisomerase II, the drug concentrations in the malignant cells during chemotherapy may have clinical correlates. Plasma protein binding of etoposide is extensive (94%) and alterations of the non-proteinbound fraction affect pharmacokinetic behavior of the drug. The p...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199309148555

    authors: Liliemark EK,Liliemark J,Pettersson B,Gruber A,Björkholm M,Peterson C

    更新日期:1993-07-01 00:00:00

  • Central venous catheter-related complications in patients with hematological malignancies: a retrospective analysis of risk factors and prophylactic measures.

    abstract:UNLABELLED:We retrospectively analyzed the incidence of thrombotic and infectious complications in relation with the use of central venous catheters (CVCs), in a series of patients with hematological malignancies and low platelet and leucocyte counts. PATIENTS AND METHODS:126 patients with hematological malignancies w...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190309178770

    authors: Cortelezzia A,Fracchiolla NS,Maisonneuve P,Moia M,Luchesini C,Ranzi ML,Monni P,Pasquini MC,Lambertenghi-Deliliers G

    更新日期:2003-09-01 00:00:00

  • Paraproteinemic neuropathy.

    abstract::Monoclonal proteins (paraproteins) may be detected in the sera in approximately 1% of the general population and are frequently associated with peripheral neuropathy. Paraproteinemic neuropathy (PPN) is most commonly associated with monoclonal gammopathy of undetermined significance, and may also occur in the context ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190903111922

    authors: Zivković SA,Lacomis D,Lentzsch S

    更新日期:2009-09-01 00:00:00

  • Idiopathic myelofibrosis associated with primary biliary cirrhosis.

    abstract::A patient with primary biliary cirrhosis (PBC) who developed idiopathic myelofibrosis (IM) is reported. The initial diagnosis of PBC was established by liver biopsy, performed after a 2-month history of constitutional symptoms associated with abnormalities of the serum liver enzymes, with typical serum immunological m...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190290012272

    authors: Hernández-Boluda JC,Jiménez M,Rosiñol L,Cervantes F

    更新日期:2002-03-01 00:00:00

  • Combination of cytarabine and topotecan in patients treated for acute myeloid leukemia with persistent disease after frontline induction.

    abstract::After a first course of induction chemotherapy, 30-40% of patients with acute myeloid leukemia (AML) do not achieve a complete response (CR). A second course of an anthracycline and intermediate-dose cytarabine (IDAC) allows a significant number of patients with persistent AML at day 14 to finally achieve a CR. We hyp...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2012.685733

    authors: Prébet T,Jean E,Autret A,Charbonnier A,Rey J,Etienne A,D'incan E,Fürst S,Arnoulet C,Blaise D,Vey N

    更新日期:2012-11-01 00:00:00

  • Current and future immunotherapeutic approaches in Hodgkin lymphoma.

    abstract::Hodgkin lymphoma (HL) has become a highly curable malignancy even in advanced stages when treated adequately. However, relapsed or refractory disease and treatment-related toxicity constitute a significant clinical challenge. Innovative approaches are thus needed to improve treatment of these mainly young patients. In...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2016.1185789

    authors: Bröckelmann PJ,Borchmann P,Engert A

    更新日期:2016-09-01 00:00:00